Related Experiment Video

Updated: Sep 27, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Hyperlipidaemias and serum cytokines in patients with coronary artery disease

Katarzyna Mizia-Stec1, Barbara Zahorska-Markiewicz, Tadeusz Mandecki

  • 1Department of Pathophysiology, Silesian University School of Medicine, Katowice, Poland. biboch@slam.katowice.pl

Acta Cardiologica
|March 11, 2003
PubMed

Insights

Coronary artery disease (CAD) patients show elevated levels of tumor necrosis factor-alpha (TNFα). Serum lipids significantly influence immune markers like TNFα, soluble TNF receptors (sTNFR), and Interleukin-10 (IL-10) in these patients.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Biochemistry

Background:

  • Atherosclerosis pathogenesis involves inflammatory processes and lipid disturbances.
  • Understanding the interplay between lipid profiles and immune markers is crucial for managing coronary artery disease (CAD).

Purpose of the Study:

  • To investigate the impact of hyperlipidemias on serum levels of tumor necrosis factor-alpha (TNFα), soluble TNF receptors (sTNFR) 1 and 2, and Interleukin-10 (IL-10).
  • To evaluate these immune markers in patients with stable CAD and varying lipid profiles.

Main Methods:

  • Study included 94 stable CAD patients categorized by lipid profiles: hypercholesterolemia (HC), mixed hyperlipidemia (HL), and normal lipids (NL).
  • Twenty healthy volunteers served as controls (C).
  • Serum levels of TNFα, sTNFR 1, sTNFR 2, and IL-10 were measured and correlated with lipid parameters (HDL-C, LDL-C, triglycerides).

Main Results:

  • CAD patients exhibited significantly higher serum TNFα levels compared to controls.
  • sTNFR 1 levels were elevated in the normal lipid group (NL) versus hypercholesterolemia (HC) and controls.
  • IL-10 levels were higher in the HC group than in controls.
  • TNFα correlated negatively with HDL-cholesterol and positively with triglycerides.
  • sTNFR 1 and IL-10 showed negative correlations with LDL-cholesterol, while sTNFR 2 showed a positive correlation.

Conclusions:

  • Stable CAD patients demonstrate increased serum TNFα concentrations.
  • Immune activation, indicated by TNFα, sTNFR 1, sTNFR 2, and IL-10, appears linked to serum lipid levels in CAD patients.
Abstract

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...